Chugai appoints new US CMO
This article was originally published in Scrip
Executive Summary
Chugai Pharma USA (CPUSA) a wholly owned subsidiary of Chugai Pharmaceutical, a Tokyo, Japan-based member of the Roche Group, has named Dr Athos Gianella-Borradori chief medical officer, CPUSA. Dr Gianella-Borradori has more than 20 years' experience in international drug research. His prior roles include senior positions in research and development at Novartis (Switzerland), Crucell (The Netherlands), Bavarian Nordic (Germany), Cyclacel (United Kingdom), Merck Serono (Switzerland) and Clavis Pharma (Norway).
You may also be interested in...
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.